Clinical Trial Update: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update assessing GNOS-PV02 personalized neoantigen vaccine in combination with INO-9012 and pembrolizumab for advanced hepatocellular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GNOS-PV02
• INO-9012 (INO-9012)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Geneos Therapeutics | Conditions: HCC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING